Attovia: $90M Series C Financing to Propel ATTOBODY Programs

Deal News | Apr 15, 2025 | Illumina Ventures

Attovia Therapeutics has announced a successful $90 million Series C financing round intended to propel its proprietary ATTOBODY-based programs through clinical proof of concept. The financing is led by Deep Track Capital, with the participation of Illumina Ventures among other new and previous investors. The funds will be allocated towards early-to-mid-stage clinical trials for the ATTO-1310 drug aimed at treating chronic pruritus and ATTO-3712 for treating atopic dermatitis. The investment will also support multiple earlier-stage multi-specific programs, highlighting a significant development phase for Attovia Therapeutics and its innovative biological technologies.

Sectors

Biotechnology
Healthcare
Pharmaceuticals

Geography

United States – The participants, including Attovia Therapeutics and Deep Track Capital, are likely based in the United States, which is a major hub for biotechnology and pharmaceutical industries.

Industry

Biotechnology – Attovia Therapeutics operates in the biotechnology sector, developing novel therapies based on their proprietary ATTOBODY technology.
Healthcare – The company is focusing on treatments for chronic pruritus and atopic dermatitis, which are critical areas within the healthcare industry.
Pharmaceuticals – The development of drugs like ATTO-1310 and ATTO-3712 situates Attovia within the pharmaceutical industry, advancing innovative therapeutic solutions.

Financials

$90 million – The total amount raised in the Series C financing round by Attovia Therapeutics.

Participants

Name	Role	Type	Description
Attovia Therapeutics	Target Company	Company	A biotechnology company advancing ATTOBODY-based drug programs.
Deep Track Capital	Bidding Company/Investor	Company	Lead investor in Attovia Therapeutics' $90 million Series C financing round.
Illumina Ventures	Investor	Company	Participated as an investor in the Series C round for Attovia Therapeutics.